|
Synonyms: CT-388 | CT388 | RO-7795068 | RO7795068
Compound class:
Peptide
Comment: Enicepatide (CT-388) is a dual GLP-1R and GIPR agonist peptide [2], with signalling bias towards cAMP accumulation (i.e., it has minimal effect on β-arrestin-2 recruitment by either receptor) that limits ligand-induced receptor internalisation [1].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use ![]() |
| Enicepatide (CT-388) was progressed as a potential anti-obesity therapeutic. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT04838405 | A Study of CT-388 in Otherwise Healthy Overweight and Obese Adults and Patients With Type 2 Diabetes Mellitus | Phase 1 Interventional | Carmot Therapeutics, Inc. | 1 | |
| NCT07351045 | A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes | Phase 3 Interventional | Hoffmann-La Roche | ||
| NCT07351058 | A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 Interventional | Hoffmann-La Roche | ||
| NCT07670416 | A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes | Phase 3 Interventional | Hoffmann-La Roche | ||